Company Description
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma.
The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.
GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 10, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Harout Semerjian |
Contact Details
Address: 9708 Medical Center Drive Rockville, Maryland 20850 United States | |
| Phone | 240 243 1201 |
| Website | glycomimetics.com |
Stock Details
| Ticker Symbol | GLYC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001253689 |
| CUSIP Number | 38000Q102 |
| ISIN Number | US38000Q1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Harout Semerjian | Chief Executive Officer |
| Brian Hahn | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 4, 2024 | SCHEDULE 13G/A | Filing |
| Oct 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 29, 2024 | 8-K | Current Report |